Seagen (NASDAQ:SGEN) Vs. AMGN, GILD, REGN, VRTX, BIIB, INCY, ALNY, BMRN, EXAS, and UTHR
Should you be buying Seagen stock or one of its competitors? The main competitors of Seagen include Amgen (AMGN), Gilead Sciences (GILD), Regeneron Pharmaceuticals (REGN), Vertex Pharmaceuticals (VRTX), Biogen (BIIB), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), and United Therapeutics (UTHR). These companies are all part of the "biotechnology" industry.
Seagen vs.
Seagen (NASDAQ:SGEN) and Amgen (NASDAQ:AMGN) are both large-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, earnings, media sentiment, valuation, risk, community ranking and dividends.
Amgen has a net margin of 21.75% compared to Seagen's net margin of -41.32%. Amgen's return on equity of 165.95% beat Seagen's return on equity.
90.4% of Seagen shares are held by institutional investors. Comparatively, 79.0% of Amgen shares are held by institutional investors. 27.3% of Seagen shares are held by insiders. Comparatively, 0.5% of Amgen shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Seagen has a beta of 0.85, indicating that its stock price is 15% less volatile than the S&P 500. Comparatively, Amgen has a beta of 0.58, indicating that its stock price is 42% less volatile than the S&P 500.
Amgen received 744 more outperform votes than Seagen when rated by MarketBeat users. Likewise, 73.96% of users gave Amgen an outperform vote while only 66.45% of users gave Seagen an outperform vote.
Seagen currently has a consensus target price of $160.00, suggesting a potential upside of 14.58%. Amgen has a consensus target price of $239.36, suggesting a potential downside of 3.29%. Given Seagen's stronger consensus rating and higher possible upside, equities research analysts plainly believe Seagen is more favorable than Amgen.
Amgen has higher revenue and earnings than Seagen. Seagen is trading at a lower price-to-earnings ratio than Amgen, indicating that it is currently the more affordable of the two stocks.
In the previous week, Amgen had 1 more articles in the media than Seagen. MarketBeat recorded 9 mentions for Amgen and 8 mentions for Seagen. Amgen's average media sentiment score of 0.33 beat Seagen's score of -0.35 indicating that Amgen is being referred to more favorably in the news media.
Summary
Amgen beats Seagen on 11 of the 18 factors compared between the two stocks.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding SGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Seagen (NASDAQ:SGEN) vs. Its Competitors
